Eric J. Delgado

Associate
Full contact info

Passions

Martial Arts

Cooking

Hiking

Travel

Experience

Cerevel Therapeutics – $253.8 Million Follow-on Offering and Concurrent $345.0 Million Rule 144A Convertible Notes Offering

September 2, 2022

Cooley advised the underwriters in Cerevel Therapeutics’ $253.8 million follow-on offering of 7,250,000 shares of its common stock at a public offering price of $35 per share and the initial purchasers in its $345.0 million Rule 144A convertible notes offering. Cerevel is a clinical-stage biopharmaceutical company pursuing a targeted approach to neuroscience that combines a deep understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system target receptor selective pharmacology to discover and design new therapies. Lawyers Div Gupta, Daniel Goldberg, Eric Blanchard, Mischi a Marca, Jason Savich, Minkyu Park, Amiti Rothstein, Ellie Guadiana, Matt Kong, Eric Delgado and Jordan Verrilli led the Cooley team.

Related contacts

Div Gupta
Partner, New York
Daniel I. Goldberg
Partner, New York
Eric Blanchard
Partner, New York
Mischi a Marca
Partner, San Francisco
Jason Savich
Partner, San Francisco
Minkyu Park
Associate, New York
Amiti C. Rothstein
Associate, New York
Ellie Guadiana
Partner, Los Angeles Santa Monica
Matt Kong
Associate, San Francisco
Eric J. Delgado
Associate, New York
Kindall G. Jackson
Associate, Washington, DC

Related Practices & Industries